Chronic myelomonocytic leukemia (CMML) is a unique myeloproliferative disease characterized by marrow dysplasia and an increase in monocytes. The median survival of patients with CMML is short, in part, because CMML is frequently resistant to therapy. A better understanding of the basic biology of CMML progenitors is needed in order to reduce regimen related toxicity and provide more effective CMML targeted therapies. To this end, a mouse transgenic model of CMML was created in which human bcl-2 overexpression was targeted to the myeloid lineage by the myeloid promoter hMRP8.